Kyverna Therapeutics, Inc. Common Stock (KYTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) has a cash flow conversion efficiency ratio of -0.285x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.32 Million) by net assets ($151.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kyverna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Kyverna Therapeutics, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
Kyverna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyverna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
0.028x |
|
Smcp SAS
PA:SMCP
|
0.110x |
|
Youlchon Chem
KO:008730
|
0.029x |
|
Masterwork Machinery
SHE:300195
|
0.014x |
|
Medistim ASA
OL:MEDI
|
0.098x |
|
Laxmi Organic Industries Limited
NSE:LXCHEM
|
0.029x |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
0.091x |
|
Chaun-Choung Technology Corp
TW:6230
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Kyverna Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see Kyverna Therapeutics, Inc. Common Stock (KYTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $266.59 Million | $-114.25 Million | -0.429x | +59.79% |
| 2023-12-31 | $49.18 Million | $-52.41 Million | -1.066x | -37.75% |
| 2022-12-31 | $46.68 Million | $-36.11 Million | -0.774x | -261.52% |
| 2021-12-31 | $-46.25 Million | $-22.16 Million | 0.479x | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also develo… Read more